Skip to main content

Table 1 Baseline characteristics

From: Procalcitonin is not an independent predictor of 30-day mortality, albeit predicts pneumonia severity in patients with pneumonia acquired outside the hospital

 

Total

< 74 years

> 75 years

P value

No. of patients

667

231

436

 

died within 30 days

66 (10.0%)

11 (4.8%)

55 (12.6%)

< 0.01*

Male / female

424 (63.6%)/243 (36.4%)

1 52 (65.8%)/79 (34.2%)

272 (62.4%)/164 (37.6%)

0.38

Age(years)

80.0 (71.0–86.0)

67.0 (55.0–71.0)

85.0 (80.0–89.0)

< 0.01*

CAP / HCAP

396 (59.4%)/271 (40.6%)

1 75 (75.8%)/56 (24.2%)

221 (50.7%)/21 5 (49.3%)

< 0.01*

PSI class

I

35 (5.3%)

35 (15.1%)

0

< 0.01*

II

84 (1 2.6%)

75 (32.5%)

9 (2.1%)

III

151 (22.6%)

50 (21.6%)

101 (23.1%)

IV

288 (43.2%)

60 (26.0%)

228 (52.3%)

V

109 (16.3%)

11 (4.8%)

98 (22.4%)

BMI(kg/m2)

19.8 (17.0–22.5)

20.0 (17.9–22.7)

19.6 (16.9–22.5)

0.10

Albumin(g/dL)

3.2 (2.8–3.6)

3.4 (2.9–3.8)

3.1 (2.7–3.5)

< 0.01*

Procalcitonin(ng/mL)

0.35 (0.10–2.09)

0.20 (0.07–0.84)

0.52 (0.13–2.66)

< 0.01*

WBC(/mm3)

10,500 (7700–14,400)

11,100 (7600–14,800)

10,300 (7700–13,900)

0.38

CRP(mg/dL)

9.09 (3.99–16.20)

9.91 (4.43–18.0)

8.01 (3.52–15.01)

< 0.01*

BUN(mg/dL)

18 (14–26)

14 (10–19)

20 (15–29)

< 0.01*

Comorbidity Charlson comorbidity index

0

224 (33.6%)

104 (45.0%)

120 (27.5%)

< 0.01*

1

244 (36.6%)

62 (26.9%)

182 (41.7%)

2

126 (18.9%)

46 (19.9%)

80 (18.4%)

3

56 (8.4%)

1 6 (6.9%)

40 (9.2%)

4

13 (1.9%)

2 (0.9%)

11 (2.5%)

5

1 (0.1%)

0 (0%)

1 (0.2%)

6

3 (0.5%)

1 (0.4%)

2 (0.5%)

Chronic lung disease

1 89 (28.3%)

69 (29.9%)

120 (27.5%)

0.53

Diabetes mellitus

128 (19.2%)

44 (19.0%)

84 (19.3%)

1.00

Dementia

123 (18.4%)

10 (4.3%)

113 (25.9%)

< 0.01*

Cerebrovascular disease

67 (10.0%)

26 (11.3%)

41 (9.4%)

0.50

Chronic heart failure

62 (9.3%)

7 (3.0%)

55 (12.6%)

< 0.01*

Malignancy

33 (4.9%)

9 (3.9%)

24 (5.5%)

0.45

Kidney disease

29 (4.3%)

6 (2.6%)

23 (5.3%)

0.12

Liver disease

15 (2.2%)

3 (1.3%)

12 (2.8%)

0.28

Pathogen Streptococcus pneumoniae

126 (18.9%)

39 (16.9%)

87 (20.0%)

0.35

Haemophilus influenzae

40 (6.0%)

14 (6.1%)

26 (6.0%)

1.00

Klebsiella pneumoniae

30 (4.5%)

5 (2.2%)

25 (5.7%)

0.04*

Escherichia coli

25 (3.7%)

3 (1.3%)

22 (5.0%)

0.01*

Pseudomonas aeruginosa

23 (3.4%)

10 (4.3%)

13 (3.0%)

0.38

Moraxella catarrhalis

16 (2.3%)

6 (2.6%)

10 (2.3%)

0.78

MSSA

13 (1.9%)

2 (0.9%)

11 (2.5%)

0.24

MRSA

11 (1.6%)

2 (0.9%)

9 (2.1%)

0.35

Serratia marcescens

8 (1.2%)

4 (1.7%)

4 (0.9%)

0.46

Enterococcus faecalis

7 (1.0%

2 (0.9%)

5 (1.1%)

1.00

Stenotrophomonas maltophilia

6 (0.9%)

2 (0.9%)

4 (0.9%)

1.00

Legionella pneumoniae

5 (0.7%)

3 (1.3%)

2 (0.5%)

0.35

Proteus merabilis

5 (0.7%)

1 (0.4%)

4 (0.9%)

0.66

Enterobacter cloacae

4 (0.6%)

1 (0.4%)

3 (0.7%)

0.66

Mycoplasma pneumoniae

30 (4.5%)

21 (9.1%)

9 (2.1%)

< 0.01*

Chlamydophila pneumoniae

22 (3.3%)

10 (4.3%)

12 (2.8%)

0.36

  1. CAP Community acquired pneumonia, HCAP Healthcare-associated pneumonia, PSI Pneumonia severity index, BMI Body mass index, WBC White blood cell, CRP C-reactive protein, BUN Blood urea nitrogen, MSSA Methicillin-sensitive Staphylococccusaureus, MRSA Methicillin-resistant Staphylococcus aureus Data are presented as number (%) or median (1st quartile - 3rd quartile)
  2. P value: < 74 years vs > 75 years * Statistically significant